Treatment-Free Survival Following Discontinuation of First-Line Nivolumab Plus Ipilimumab or Sunitinib

Thomas Powles Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, Royal Free NHS Trust, London, UK discusses Treatment-Free Survival Following Discontinuation... Author: kidneycancer Added: 11/05/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts